Clinical Trials Logo
  1. Home
  2. Limb Girdle Muscular Dystrophy
  3. NCT02635321

MRI and Muscle Involvement in Patients With Mutations in GMPPB

Limb-girdle Muscular Dystrophy Clinical Trial

Official title:
MRI and Muscle Involvement in Patients With Mutations in GMPPB

Clinical Trial Summary

Limb girdle muscular dystrophies (LGMD) are a very heterogeneous group of muscle disorders characterized by muscle weakness and atrophy of the proximal muscles of the shoulder and pelvic girdles. LGMD is classified based on its inheritance pattern and genetic cause into more than 31 different types.

A new type - type 2T has been found. The genetic cause of type 2T is mutations in Guanosine Diphosphate (GDP)-mannose pyrophosphorylase B (GMPPB). Mutations in GMPPB can also cause Congenital muscular dystrophies (CMD). Only 41 patients with mutations in GMPPB has been reported.

In this study, the investigators examine five new cases with the LGMD phenotype. The primary aim is to examine the muscle involvement using MRI.

Clinical Trial Description

n/a

Study Design

Observational Model: Case-Only, Time Perspective: Cross-Sectional

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02635321
Study type Observational
Source Rigshospitalet, Denmark
Contact
Status Completed
Phase N/A
Start date November 2015
Completion date April 2016
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT01403402 - Congenital Muscle Disease Study of Patient and Family Reported Medical Information
Terminated NCT03783923 - A Study of Deflazacort (Emflaza®) in Participants With Limb-Girdle Muscular Dystrophy 2I (LGMD2I) Phase 3
Completed NCT00873782 - Safety Study of Transvenous Limb Perfusion in Human Muscular Dystrophy Phase 1
Completed NCT00457912 - Genetic Characterization of Individuals With Limb Girdle Muscular Dystrophy N/A
Completed NCT04054375 - Weekly Steroids in Muscular Dystrophy Phase 2
Recruiting NCT00390104 - Molecular Analysis of Patients With Neuromuscular Disease
Recruiting NCT06246513 - A Trial to Learn More About an Experimental Gene Therapy Called Bidridistrogene Xeboparvovec (SRP-9003) as a Possible Treatment for Limb Girdle Muscular Dystrophy 2E/R4 (EMERGENE) Phase 3
Completed NCT00104078 - Study Evaluating MYO-029 in Adult Muscular Dystrophy Phase 1/Phase 2
Recruiting NCT04475926 - A Study of the Natural History of Participants With LGMD2E/R4, LGMD2D/R3, LGMD2C/R5, and LGMD2A/R1 ≥ 4 Years of Age, Who Are Managed in Routine Clinical Practice
Completed NCT02759302 - MRI on Persons With Mutations in POMT2 Gene (LGMD2N) N/A